CD274 and neoplasm: These reconfigured receptors, both γ-TCRγδ and δ-TCRγδ, are capable of transducing signals, producing inflammatory cytokines, degranulating and exerting tumor killing activity upon engagement with PD-L1 antigen in vitro.